olanzapine and 4-hydroxybutyric-acid

GHB is an increasingly popular drug of abuse that can be associated in select cases with growing dependence and a severe withdrawal syndrome. While benzodiazepines are recommended for treatment of the withdrawal syndrome, some cases have been described as benzodiazepine-resistant. The authors describe treatment of such a case, which was unsuccessfully treated initially with benzodiazepines, then successfully treated with adjuvant atypical neuroleptics, and offer a possible neurochemical explanation for why such agents may be theoretically more effective than benzodiazepines in treating GHB withdrawal.

Topics: Adjuvants, Anesthesia; Adult; Antipsychotic Agents; Benzodiazepines; Humans; Hydroxybutyrates; Male; Olanzapine; Substance Withdrawal Syndrome; Treatment Failure